195 related articles for article (PubMed ID: 38383524)
1. Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy.
Hoogenboezem EN; Patel SS; Lo JH; Cavnar AB; Babb LM; Francini N; Gbur EF; Patil P; Colazo JM; Michell DL; Sanchez VM; McCune JT; Ma J; DeJulius CR; Lee LH; Rosch JC; Allen RM; Stokes LD; Hill JL; Vickers KC; Cook RS; Duvall CL
Nat Commun; 2024 Feb; 15(1):1581. PubMed ID: 38383524
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy.
Hoogenboezem EN; Patel SS; Cavnar AB; Lo JH; Babb LM; Francini N; Patil P; Colazo JM; Michell DL; Sanchez VM; McCune JT; Ma J; DeJulius CR; Lee LH; Rosch JC; Allen RM; Stokes LD; Hill JL; Vickers KC; Cook RS; Duvall CL
bioRxiv; 2023 Feb; ():. PubMed ID: 36824780
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
4. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
Biscans A; Coles A; Echeverria D; Khvorova A
J Control Release; 2019 May; 302():116-125. PubMed ID: 30940496
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.
Sarett SM; Werfel TA; Lee L; Jackson MA; Kilchrist KV; Brantley-Sieders D; Duvall CL
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6490-E6497. PubMed ID: 28739942
[TBL] [Abstract][Full Text] [Related]
6. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
7. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
Zhao Z; Li Y; Liu H; Jain A; Patel PV; Cheng K
Sci Adv; 2020 Jul; 6(29):eabb0616. PubMed ID: 32832636
[No Abstract] [Full Text] [Related]
10. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
11. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
14. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
17. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
18. Targeted silencing of the MCL-1 gene using multi-layered dendrimer-based nanoconstructs achieves efficient tumor regression in xenografted mice models.
Tambe P; Salve R; Choudhary P; Kumar P; Jadhav S; Paknikar KM; Gajbhiye V
Int J Pharm; 2023 Mar; 634():122659. PubMed ID: 36720446
[TBL] [Abstract][Full Text] [Related]
19. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
Yang Z; Liu T; Xie Y; Sun Z; Liu H; Lin J; Liu C; Mao ZW; Nie S
Acta Biomater; 2015 Oct; 25():194-204. PubMed ID: 26193000
[TBL] [Abstract][Full Text] [Related]
20. Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC.
Kumar P; Salve R; Paknikar KM; Gajbhiye V
Int J Biol Macromol; 2023 Feb; 229():600-614. PubMed ID: 36586658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
